News Briefing channel feed

6 Di­men­sions backs Lyv­gen's $30M B round; No­var­tis hands off glob­al rights to IL-2 drug

7 years ago

FDA ex­perts back GSK's new malar­ia drug; Sang­amo's new­ly mint­ed CTO jumps to biotech up­start

7 years ago

Tai­ho kicks off $130M Ar­cus deal with drug op­tion; J&J al­lies with Mer­ck KGaA to take di­a­betes drug to Chi­na

7 years ago

In­ves­tiga­tive re­port calls for re­newed scruti­ny on Aca­dia drug; Im­bru­vi­ca fails in front­line DL­B­CL PhI­II

7 years ago

Bris­tol-My­ers Squib­b's Op­di­vo/Yer­voy com­bo scores col­orec­tal can­cer OK; For­mer Ake­bia, Mer­ri­mack staffers found guilty

7 years ago

An­ti­body mak­er Vac­cinex files $46M IPO tout­ing I/O com­bo drug; Replimune shoots for $100M-plus in IPO

7 years ago

Chi­na to cut can­cer drug prices; Nim­bus nabs Gilead­'s Adri­an Ray to serve as SVP of dis­cov­ery bi­ol­o­gy

7 years ago

FDA OKs Xeomin in fourth in­di­ca­tion; Nextbi­otix rais­es $8M for mi­cro­bio­me tech

7 years ago

Mer­ck scores pri­or­i­ty re­view Keytru­da in squa­mous NSCLC; Syn­thet­ic Ge­nomics spin­out SGI-DNA gets new CEO

7 years ago

MiMedx shares swoon as purge claims CEO; Those big cuts in drug prices you heard about? Pfiz­er has oth­er ideas

7 years ago

No­var­tis to spin off Al­con eye care unit, buy back $5B in stock; Ri­val CAR-Ts from No­var­tis and Gilead get thumbs up in Eu­rope

7 years ago

As Alex­ion fields ap­pli­ca­tions for ALXN1210, a ri­val aims for the crown with head-to-head PhI­II; No­vo hands NBE €20M

7 years ago

Chi­nese I/O play­er Ad­lai Nortye wraps $50M Se­ries B; Am­gen touts PhI­II da­ta for Rem­i­cade knock­off

7 years ago

Roche's So­phie Ko­rnows­ki joins Chris Viehbach­er at Gur­net Point; FDA will give Roche's ground­break­ing flu drug speedy re­view

7 years ago

De­men­tia Dis­cov­ery Fund clos­es $350M, re­cruits Cel­gene ex­ec as CEO; Ex-Lazard banker Ian Woo joins C-Bridge and Ever­est

7 years ago

Nanobi­otix shares rock­et up on a mar­gin­al suc­cess for soft tis­sue sar­co­ma; As­traZeneca wins pi­o­neer­ing PD-L1 OK in In­dia

7 years ago

AdoRx rais­es $10M for adeno­sine pro­gram in can­cer; Mol­e­c­u­lar Part­ners poach­es Re­gen­eron, re­cruit­ing Pamela Trail as CSO

7 years ago

Cel­gene/Re­cep­tos ex­ec jumps to Ku­ra as new COO; TG Ther­a­peu­tics al­lies with Novim­mune on $185M bis­pe­cif­ic deal

7 years ago

Alex­ion shoots for fast re­view of Soliris suc­ces­sor us­ing a PRV; San­doz wades in­to med­ical cannabis busi­ness

7 years ago

Sev­en biotech IPOs ready to roll; Cell­tri­on's Her­ceptin biosim gets sec­ond re­view at FDA

7 years ago

Sanofi sells man­u­fac­tur­ing site to Re­ci­pharm; Ap­tose buys rights to sell Crys­talGe­nomic­s' can­cer drug in Chi­na

7 years ago

Bridge­Bio dou­bles down on rare dis­ease with CoA launch; Be­lea­guered scPhar­ma­ceu­ti­cal­s' shares wilt again on FDA's re­jec­tion let­ter

7 years ago

Idera shares slide on PhII fail­ure; WuXi blue­prints $60M man­u­fac­tur­ing cen­ter in Worces­ter, MA

7 years ago

Bridge­Bio bags Alex­ion's ul­tra-rare dis­ease as­set; Al­ler­gan touts a new set of late-stage da­ta for oral CGRP drug

7 years ago
First page Previous page 58596061626364 Next page Last page
A service from the Financial Times